The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Venetoclax and navitoclax combination therapy for R/R ALL or lymphoblastic lymphoma
In this video, Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, discusses results from a multicenter retrospective analysis comparing venetoclax and navitoclax in combination with chemotherapy to venetoclax and navitoclax alone for the treatment of relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) (NCT03181126). Dr Chiaretti highlights the overall response rate (ORR) observed and further comments on the possibility of using this combination as a bridge to allogeneic transplant. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer: Other: advisory board; Gilead: Other: advisory board; Abbvie: Other: advisory board; Incyte: Other: advisory board; Amgen: Other: advisory board.
